Pharmaceutical composition and a process to prepare the same

A pharmaceutical composition comprising the compound of Formula IV or its pharmaceutically acceptable salt thereof,

• wherein R6 and R7 each independently is selected from —H, alkoxy, alkyl, substituted or unsubstituted aromatic group, —NH2, —NO2, —NHCOCH3, —CN, —O—, halogen, —OCF3 or R6 and R7 together form a heterocyclic ring;
• R11 and R12 each independently is selected from —H, or R11 and R12 can be substituted or unsubstituted 5- or 6-membered ring such as lactone, —C(O)O-alkyl such as —C(O)OC2H5;
• R is selected from
• —H, —C(O)CH2Cl, —SOO—CH3, —SOOPh, —CH2C(O)N(CH3)2, —C(O)NHPh, —C(O)NHPhOH, —C(S)NHPh, —CH2Ph, —COAr, —SOOAr, —CONHAr, —CH2Ar, —CSNHAr, wherein, R13 is selected from —OH, —NH2, —NHCOCH3, X═F, Cl, Br, alkyl, acetyl, C3-C8 acyl group;
• R14 is selected from alkoxy, —OMe, —OH, NH2, —NHCOCH3, X═F, Cl, Br, alkyl, acetyl, C3-C8 acyl group;
• R15 is selected from alkoxy, —OMe, —OH, —H, Br, NH2, X═F, Cl, Br, alkyl, acetyl, C3-C8 acyl group;
• R16 is selected from —H, —CH2OH, —OH, alkyl, alkoxy, R17 is selected from alkyl;
• and a solubilizing agent, further wherein the compound or a pharmaceutically acceptable salt of Formula IV, in the said pharmaceutical composition is amorphous.